Evidence map›Paper›PMID 39105827›Full record

ArticleCancer immunology, immunotherapy : CII2024

First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.

Qi Zhao, Xi Su, Jiao Xue, Yandong Liu, Jiaxing Zhu, Xuwei Cai, Songbing Qin

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qi Zhao *Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Xi Su *Department of Radiation Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.
Jiao XueDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Yandong LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Jiaxing ZhuDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Xuwei CaiDepartment of Radiation Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China. birdhome2000@163.com.
Songbing QinDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. qin92244@163.com.

Funding

Emerging Advanced Technology Joint Research Project of Shanghai Shenkang Hospital Development Center SHDC12017103Jiangsu Provincial Medical Key Discipline ZDXK202235National Natural Science Foundation of China 82073337National Natural Science Foundation of China K112201720Scientific research project of Suzhou Health Talents GSWS2020007Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support 20161433
6 · The paper itself

Abstract

There is growing evidence to suggest that radiotherapy might enhance the efficacy of immunotherapy. This study aimed to assess the possibility of KN046, a bispecific antibody targeting PD-L1 and CTLA-4, combined with chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma (ESCC). In this open-label, phase Ib trial, patients with advanced ESCC were administered chemotherapy with palliative radiotherapy, and KN046 in the predefined escalation dosages of 1, 3, or 5 mg/kg (every 3 weeks during chemotherapy cycles and every 2 weeks during KN046 maintenance). The chemotherapy regimen constituted cisplatin (75 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAdultAgedAntibodies, BispecificAntibodies, Monoclonal, HumanizedCisplatinFemaleHumansMaleMiddle AgedPalliative CareAntibodies, BispecificAntibodies, Monoclonal, HumanizedCisplatintoripalimabBispecific antibodiesChemoradiotherapyEsophageal squamous cell carcinomaImmune checkpoint inhibitors

Identifiers

PMID39105827
PMCPMC11303366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.